ClinicalTrials.gg
CompletedNCT07296146Updated Oct 30, 2026

Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.

A Phase 3 interventional study of Erythropoietin + Probiotic and EPO in Anaemia, Chronic Kidney Disease and Regular Hemodialysis, sponsored by Badr University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Badr University · Phase 3, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedFirst site in Egypt+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing erythropoietin in Anemia — 2 open to participants now, 2 under way, 1 of them phase 3. Erythropoietin · Anemia.

Enrollment
15th of 21
80 · median 104
Started
2026
the only one that year
Phase 3
11 of 23
1 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Badr University

Among the 23 studies testing erythropoietin in Anemia, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 11 in phase 3, and was the 23rd registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 23 studies testing erythropoietin in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About erythropoietin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing erythropoietin in Anemia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are:

Can probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients.

Participants will:

Take Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms

03

Conditions studied

  • Anaemia
  • Chronic Kidney Disease
  • Regular Hemodialysis

Keywords

  • Probiotic
  • erythropoietin
  • resistant anaemia
  • chronic kidney disease patients
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with end stage renal disease for more than 3 months on regular hemodialysis ( less than 15 ml/min/m2
  • Receiving stable doses of erythropoietin therapy
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Recent probiotic, antibiotic, or therapy
  • Microcytic hypochromic anemia.
  • Patients with hyperparathyroidism
  • Recent or planned kidney transplantation Gastrointestinal disorders (active IBD, cancer)
  • Pregnancy or lactation
  • Severe comorbidities (e.g., active infection, )
  • Cognitive or physical inability to comply with protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    EPO + Probiotic

    EPO (4000 IU) + Probiotic

    Drug: Erythropoietin + Probiotic

  • Active comparator
    EPO

    Erythropoietin (Epoetin 4000 IU)

    Drug: EPO

Interventions

06

What researchers measure

Primary outcomes

  1. - Hemoglobin concentration

    \- Hemoglobin concentration (g/dL)at 2 weeks, and 3-months postintervention

    Time frame: at baseline, and 3-months postintervention

  2. - Erythropoietin resistance index (ERI)

    \- ERI = (ESA dose per week) / (body weight) / (hemoglobin level).

    Time frame: at baseline, and 3-months postintervention

Secondary outcomes

  1. Serum creatine

    mg/dl

    Time frame: at baseline, and monthly (after 1,2,3 moths)

  2. Urea Reduction Ratio

    Time frame: at baseline, and monthly (after 1,2,3 moths)

07

Study locations

1 site
  • Badr University Hospital
    Cairo, Dr 11829, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Aug 2026, 6 months.

Of 50 non-industry phase 3 interventional studies under Anemia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 6 months is below that.

Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Dec 2025 → Feb 2026, primary completion Mar 2026 → Aug 2026 and completion May 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 22, 2025
StartActual
Feb 1, 2026was Dec 2025
Primary completionActual
Aug 1, 2026was Mar 2026
CompletionActual
Aug 15, 2026was May 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 30, 2026
Sites
1 site added — first site in Egypt
Show site
  • Badr University Hospital · Cairo, Egypt
Oct 30, 2026
Start date
Dec 15, 2025→Feb 1, 2026 (actual)
Oct 30, 2026
Primary completion
Mar 15, 2026→Aug 1, 2026 (actual)
Oct 30, 2026
Study completion
May 15, 2026→Aug 15, 2026 (actual)
Oct 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • Description- Hemoglobin concentration: how it is measured was reworded
Oct 30, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • Editedserum ureaSerum creatineTime frame: at baseline, and 3-months postintervention → at baseline, and monthly (after 1,2,3 moths)
  • ChangedBefore C-reactive proteinNow Urea Reduction RatioTime frame: at baseline, and 3-months postintervention → at baseline, and monthly (after 1,2,3 moths)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Completed
    1 site added — first site in Egypt
    Show site
    • Badr University Hospital · Cairo, Egypt
    Start date Dec 15, 2025→Feb 1, 2026 (now actual)
    Primary completion Mar 15, 2026→Aug 1, 2026 (now actual)
    Study completion May 15, 2026→Aug 15, 2026 (now actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • Description- Hemoglobin concentration: how it is measured was reworded
    Secondary outcomes 2 edited
    What changed in the outcomes
    • Editedserum ureaSerum creatineTime frame: at baseline, and 3-months postintervention → at baseline, and monthly (after 1,2,3 moths)
    • ChangedBefore C-reactive proteinNow Urea Reduction RatioTime frame: at baseline, and 3-months postintervention → at baseline, and monthly (after 1,2,3 moths)
    + 3 other changes: verification date, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07296146
Lead sponsor
Badr University
Responsible party
Eman Said Sawan (Lecturer, Badr University) — Principal investigator
First posted
Dec 22, 2025
Start date
Feb 1, 2026
Primary completion
Aug 1, 2026
Completion
Aug 15, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erythropoietin · Probiotic

Start the discussion